Emerging polymeric nanocarriers for mRNA and protein therapeutics: design, challenges, and clinical outlook.

IF 3.9
Nanomedicine (London, England) Pub Date : 2025-09-01 Epub Date: 2025-08-05 DOI:10.1080/17435889.2025.2542110
Chloe Forenzo, Noah Arnold, Jessica Larsen
{"title":"Emerging polymeric nanocarriers for mRNA and protein therapeutics: design, challenges, and clinical outlook.","authors":"Chloe Forenzo, Noah Arnold, Jessica Larsen","doi":"10.1080/17435889.2025.2542110","DOIUrl":null,"url":null,"abstract":"<p><p>As the healthcare landscape rapidly evolves to include advanced drug delivery methods with better cellular targeting and more efficient delivery, polymeric nanocarriers have emerged to close translational gaps. Acting on the central dogma of molecular biology, mRNA and protein therapeutics can offer curative potential for various debilitating diseases. Considering these advancements, polymeric nanocarriers have been widely explored preclinically in delivering both proteins and mRNA for various disease therapies. This review introduces how the next generation of polymeric nanocarriers can be designed for protein therapeutics, including some advantages and disadvantages as well as specific design considerations for mRNA vs protein delivery. The evolution of these polymeric nanocarriers is then examined, and the current landscape and emerging trends are presented. Finally, we provide an outlook on the clinical translation of polymeric nanocarrier delivery of mRNA and proteins, including a future perspective for the field. Despite the preclinical promise of these delivery systems in both mRNA and protein constructs, clinical translation is underwhelming. Continued development of polymeric nanocarriers is underway and early clinical trials have provided a foothold into translation for this technology. A key challenge for polymeric nanomedicine is bridging the gap between promising preclinical data and successful clinical translation.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"2357-2374"},"PeriodicalIF":3.9000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12413044/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17435889.2025.2542110","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/5 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

As the healthcare landscape rapidly evolves to include advanced drug delivery methods with better cellular targeting and more efficient delivery, polymeric nanocarriers have emerged to close translational gaps. Acting on the central dogma of molecular biology, mRNA and protein therapeutics can offer curative potential for various debilitating diseases. Considering these advancements, polymeric nanocarriers have been widely explored preclinically in delivering both proteins and mRNA for various disease therapies. This review introduces how the next generation of polymeric nanocarriers can be designed for protein therapeutics, including some advantages and disadvantages as well as specific design considerations for mRNA vs protein delivery. The evolution of these polymeric nanocarriers is then examined, and the current landscape and emerging trends are presented. Finally, we provide an outlook on the clinical translation of polymeric nanocarrier delivery of mRNA and proteins, including a future perspective for the field. Despite the preclinical promise of these delivery systems in both mRNA and protein constructs, clinical translation is underwhelming. Continued development of polymeric nanocarriers is underway and early clinical trials have provided a foothold into translation for this technology. A key challenge for polymeric nanomedicine is bridging the gap between promising preclinical data and successful clinical translation.

用于mRNA和蛋白质治疗的新兴聚合纳米载体:设计、挑战和临床前景。
随着医疗保健领域的迅速发展,包括具有更好的细胞靶向性和更有效的递送的先进药物递送方法,聚合物纳米载体已经出现,以缩小翻译差距。根据分子生物学的中心法则,mRNA和蛋白质疗法可以为各种衰弱性疾病提供治疗潜力。考虑到这些进展,聚合物纳米载体已被广泛探索用于临床前递送蛋白质和mRNA用于各种疾病治疗。本文介绍了如何设计用于蛋白质治疗的下一代聚合物纳米载体,包括一些优点和缺点以及mRNA和蛋白质递送的具体设计考虑。然后对这些聚合物纳米载体的演变进行了研究,并提出了当前的前景和新兴趋势。最后,我们展望了聚合纳米载体递送mRNA和蛋白质的临床翻译,包括该领域的未来前景。尽管这些传递系统在mRNA和蛋白质结构上的临床前应用前景很好,但临床翻译却不尽如人意。聚合物纳米载体的持续发展正在进行中,早期的临床试验为这项技术的转化提供了一个立足点。聚合物纳米医学的一个关键挑战是弥合有希望的临床前数据和成功的临床转化之间的差距。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信